Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center.

International journal of molecular sciences·2026

Same author

Improvement in health‑related quality of life in patients with heavy menstrual bleeding after treatment and its association with hereditary bleeding disorders.

BMC women's health·2026

Same author

Testing an Adapted Auditory Verbal Learning Test Paradigm for fMRI to Lateralize Verbal Memory in Patients with Epilepsy.

AJNR. American journal of neuroradiology·2022

Same author

Clinicopathological features, MCPyV status and outcomes of Merkel cell carcinoma in solid-organ transplant recipients: a retrospective, multicentre cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Same author

Role of PCA3 and SelectMDx in the optimization of active surveillance in prostate cancer.

Actas urologicas espanolas·2021

Same author

Cytocompatibility and bioactive properties of the new dual-curing resin-modified calcium silicate-based material for vital pulp therapy.

Clinical oral investigations·2021

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Translational Orthotopic Models of Glioblastoma Multiforme

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

Concurrent EGFR amplification and TP-53 mutation in glioblastomas.

R Gil-Benso¹, C Lopez-Gines, R Benito

¹Department of Pathology, Medical School, University of Valencia, Av. Blasco Ibanez, 15, 46010 Valencia, Spain. Rosario.Gil-Benso@uv.es

Clinical Neuropathology

|October 3, 2007

Summary

This study investigated two glioblastoma cases with concurrent epidermal growth factor receptor gene amplification and TP-53 mutations, previously thought to be mutually exclusive. Findings reveal shared chromosomal abnormalities and distinct molecular alterations in primary and secondary glioblastomas.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jul 11, 2026

Translational Orthotopic Models of Glioblastoma Multiforme

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

Neuro-oncology
Cancer Genetics
Molecular Pathology

Background:

Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with a poor prognosis, often treated with palliative conventional therapies.
Genetic alterations like epidermal growth factor receptor gene (EGFR) amplification and TP-53 mutations are key in GBM pathogenesis, typically distinguishing primary from secondary tumors.
EGFR amplification is more common in primary GBM, while TP-53 mutations are prevalent in low-grade gliomas and secondary GBM.

Observation:

This study presents a histological and genetic analysis of two GBM cases: one primary (de novo) and one secondary (arising from anaplastic astrocytoma).
Both cases exhibited concurrent EGFR amplification and TP-53 mutation, challenging the notion that these genetic alterations are mutually exclusive.
Cytogenetic analysis revealed common monosomy of chromosomes 10 and 17 in both GBM cases.

Findings:

The secondary GBM case presented a rare TP-53 mutation.
Hypermethylation of the p16(INK4a) promoter region was observed in the primary GBM.
Hypermethylation of the p14(ARF) promoter region was identified in the secondary GBM.

Implications:

These findings expand the understanding of GBM genetic heterogeneity and the co-occurrence of specific molecular alterations.
The study highlights the importance of comprehensive genetic profiling in GBM for potential therapeutic strategies.
Further research into the interplay of these genetic anomalies may uncover novel therapeutic targets for glioblastoma treatment.